Swedish Orphan (Germany) Today
| B6E Stock | EUR 26.48 1.06 3.85% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Swedish Orphan is trading at 26.48 as of the 21st of December 2024. This is a 3.85% down since the beginning of the trading day. The stock's lowest day price was 26.48. Swedish Orphan has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of November 2024 and ending today, the 21st of December 2024. Click here to learn more.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. The company has 295.99 M outstanding shares. More on Swedish Orphan Biovitrum
Moving against Swedish Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Swedish Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Swedish Orphan's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Swedish Orphan or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
Swedish Orphan Biovitrum (B6E) is traded on Frankfurt Exchange in Germany and employs 1,556 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.36 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Swedish Orphan's market, we take the total number of its shares issued and multiply it by Swedish Orphan's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Swedish Orphan Biovitrum classifies itself under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 295.99 M outstanding shares.
Swedish Orphan Biovitrum has accumulated about 280.15 M in cash with 5.47 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Check Swedish Orphan Probability Of Bankruptcy
Ownership AllocationSwedish Orphan Biovitrum shows a total of 295.99 Million outstanding shares. Over half of Swedish Orphan's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Swedish Orphan Biovitrum. Please watch out for any change in the institutional holdings of Swedish Orphan as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Swedish Ownership Details
Swedish Orphan Biovitrum Risk Profiles
Although Swedish Orphan's alpha and beta are two of the key measurements used to evaluate Swedish Orphan's performance over the market, the standard measures of volatility play an important role as well.
Swedish Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Swedish Orphan without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
Swedish Orphan Corporate Management
Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Konstantina Karampela | Director Operations | Profile | |
| Christine Wesstrom | Head Operations | Profile | |
| Guido Oelkers | CEO Pres | Profile | |
| Thomas Larsen | Head Relations | Profile | |
| Pablo Mora | Head Access | Profile | |
| Armin MD | Head Affairs | Profile | |
| Philip Wood | Head Haematology | Profile |
Other Information on Investing in Swedish Stock
Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.